

References

1. Lander, E.S. and N.J. Schork, *Genetic dissection of complex traits*. Science, 1994. **265**(5181): p. 2037-48.
2. Livshits, G., *Growth and development of bodyweight, height and head circumference during the first two years of life: quantitative genetic aspects*. Ann Hum Biol, 1986. **13**(4): p. 387-96.
3. Mueller, W.H., *Parent-child correlations for stature and weight among school aged children: A review of 24 studies*. Hum Biol, 1976. **48**(2): p. 379-97.
4. Rao, D.C., et al., *Analysis of family resemblance. V. Height and weight in northeastern Brazil*. Am J Hum Genet, 1975. **27**(4): p. 509-20.
5. Bogin, B. and L. Rios, *Rapid morphological change in living humans: implications for modern human origins*. Comp Biochem Physiol A Mol Integr Physiol, 2003. **136**(1): p. 71-84.
6. Singhal, A., et al., *Early nutrition and leptin concentrations in later life*. Am J Clin Nutr, 2002. **75**(6): p. 993-9.
7. World Health Organization. *Cardiovascular diseases (CVDs)*. [online] 2018 27 Jul. 2018]; Available from: [http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)).
8. McGill, H.C., Jr., C.A. McMahan, and S.S. Gidding, *Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study*. Circulation, 2008. **117**(9): p. 1216-27.
9. Gersh, B.J., et al., *Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications*. Eur Heart J, 2010. **31**(6): p. 642-8.
10. Teo, K.K. and H. Dokainish, *The Emerging Epidemic of Cardiovascular Risk Factors and Atherosclerotic Disease in Developing Countries*. Can J Cardiol, 2017. **33**(3): p. 358-365.
11. Gaziano, T.A., et al., *Growing epidemic of coronary heart disease in low- and middle-income countries*. Curr Probl Cardiol, 2010. **35**(2): p. 72-115.
12. Kathiresan, S. and D. Srivastava, *Genetics of human cardiovascular disease*. Cell, 2012. **148**(6): p. 1242-57.
13. Finegold, J.A., P. Asaria, and D.P. Francis, *Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations*. Int J Cardiol, 2013. **168**(2): p. 934-45.
14. Borrell, L.N., *The effects of smoking and physical inactivity on advancing mortality in U.S. adults*. Ann Epidemiol, 2014. **24**(6): p. 484-7.
15. de Souza, R.J., et al., *Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies*. BMJ, 2015. **351**: p. h3978.
16. Baldo, M.P., S.L. Rodrigues, and J.G. Mill, *High salt intake as a multifaceted cardiovascular disease: new support from cellular and molecular evidence*. Heart Fail Rev, 2015. **20**(4): p. 461-74.
17. Fernandez-Sola, J., *Cardiovascular risks and benefits of moderate and heavy alcohol consumption*. Nat Rev Cardiol, 2015. **12**(10): p. 576-87.
18. O'Donnell, M.J., et al., *Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study*. Lancet, 2010. **376**(9735): p. 112-23.
19. Eckel, R.H., *Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association*. Circulation, 1997. **96**(9): p. 3248-50.
20. Navar-Boggan, A.M., et al., *Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease*. Circulation, 2015. **131**(5): p. 451-8.
21. Rimm, E.B., et al., *Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men*. Am J Epidemiol, 1995. **141**(12): p. 1117-27.

22. Evans, M.F. and J. Frank, *Body weight and mortality among women*. Can Fam Physician, 1997. **43**: p. 455.
23. Khaodhriar, L., K.C. McCowen, and G.L. Blackburn, *Obesity and its comorbid conditions*. Clin Cornerstone, 1999. **2**(3): p. 17-31.
24. Taylor, V.H., et al., *The impact of obesity on quality of life*. Best Pract Res Clin Endocrinol Metab, 2013. **27**(2): p. 139-46.
25. World Health Organization. *Diabetes mellitus [online]*. 2018 27 Jul. 2018]; Available from: <http://www.who.int/mediacentre/factsheets/fs138/en/>.
26. Al-Goblan, A.S., M.A. Al-Alfi, and M.Z. Khan, *Mechanism linking diabetes mellitus and obesity*. Diabetes Metab Syndr Obes, 2014. **7**: p. 587-91.
27. Tancredi, M., et al., *Excess Mortality among Persons with Type 2 Diabetes*. N Engl J Med, 2015. **373**(18): p. 1720-32.
28. Teramoto, T., et al., *Primary hyperlipidemia*. J Atheroscler Thromb, 2008. **15**(2): p. 49-51.
29. Chait, A. and J.D. Brunzell, *Acquired hyperlipidemia (secondary dyslipoproteinemias)*. Endocrinol Metab Clin North Am, 1990. **19**(2): p. 259-78.
30. Wray, N. and P. Visscher, *Estimating trait heritability*. Nature Education, 2008. **1**(1): p. 29.
31. Hill, W.G., M.E. Goddard, and P.M. Visscher, *Data and theory point to mainly additive genetic variance for complex traits*. PLoS Genet, 2008. **4**(2): p. e1000008.
32. Plomin, R. and D. Daniels, *Why are children in the same family so different from one another?* Int J Epidemiol, 2011. **40**(3): p. 563-82.
33. Boomsma, D., A. Busjahn, and L. Peltonen, *Classical twin studies and beyond*. Nat Rev Genet, 2002. **3**(11): p. 872-82.
34. Mook-Kanamori, D.O., et al., *Heritability estimates of body size in fetal life and early childhood*. PLoS One, 2012. **7**(7): p. e39901.
35. Sauce, B. and L.D. Matzel, *The paradox of intelligence: Heritability and malleability coexist in hidden gene-environment interplay*. Psychol Bull, 2018. **144**(1): p. 26-47.
36. Burton, P.R., M.D. Tobin, and J.L. Hopper, *Key concepts in genetic epidemiology*. Lancet, 2005. **366**(9489): p. 941-51.
37. Elks, C.E., et al., *Variability in the heritability of body mass index: a systematic review and meta-regression*. Front Endocrinol (Lausanne), 2012. **3**: p. 29.
38. Kettunen, J., et al., *Genome-wide association study identifies multiple loci influencing human serum metabolite levels*. Nat Genet, 2012. **44**(3): p. 269-76.
39. Yang, J., et al., *GCTA: a tool for genome-wide complex trait analysis*. Am J Hum Genet, 2011. **88**(1): p. 76-82.
40. Speed, D., et al., *Reevaluation of SNP heritability in complex human traits*. Nat Genet, 2017. **49**(7): p. 986-992.
41. Yang, J., et al., *Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index*. Nat Genet, 2015. **47**(10): p. 1114-20.
42. Bulik-Sullivan, B.K., et al., *LD Score regression distinguishes confounding from polygenicity in genome-wide association studies*. Nat Genet, 2015. **47**(3): p. 291-5.
43. Loh, P.R., et al., *Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis*. Nat Genet, 2015. **47**(12): p. 1385-92.
44. Kerem, B., et al., *Identification of the cystic fibrosis gene: genetic analysis*. Science, 1989. **245**(4922): p. 1073-80.
45. Riordan, J.R., et al., *Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA*. Science, 1989. **245**(4922): p. 1066-73.
46. Koenig, M., et al., *Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals*. Cell, 1987. **50**(3): p. 509-17.
47. Strathdee, C.A., et al., *Cloning of cDNAs for Fanconi's anaemia by functional complementation*. Nature, 1992. **356**(6372): p. 763-7.

48. *A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.* Cell, 1993. **72**(6): p. 971-83.
49. Gusella, J.F., et al., *A polymorphic DNA marker genetically linked to Huntington's disease.* Nature, 1983. **306**(5940): p. 234-8.
50. Hutchison, K.E., et al., *Population stratification in the candidate gene study: fatal threat or red herring?* Psychol Bull, 2004. **130**(1): p. 66-79.
51. Todorov, A.A. and D.C. Rao, *Trade-off between false positives and false negatives in the linkage analysis of complex traits.* Genet Epidemiol, 1997. **14**(5): p. 453-64.
52. Tabor, H.K., N.J. Risch, and R.M. Myers, *Candidate-gene approaches for studying complex genetic traits: practical considerations.* Nat Rev Genet, 2002. **3**(5): p. 391-7.
53. Roberts, S.B., et al., *Replication of linkage studies of complex traits: an examination of variation in location estimates.* Am J Hum Genet, 1999. **65**(3): p. 876-84.
54. Lander, E. and L. Kruglyak, *Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.* Nat Genet, 1995. **11**(3): p. 241-7.
55. Altmuller, J., et al., *Genomewide scans of complex human diseases: true linkage is hard to find.* Am J Hum Genet, 2001. **69**(5): p. 936-50.
56. Risch, N. and K. Merikangas, *The future of genetic studies of complex human diseases.* Science, 1996. **273**(5281): p. 1516-7.
57. Reich, D.E. and E.S. Lander, *On the allelic spectrum of human disease.* Trends Genet, 2001. **17**(9): p. 502-10.
58. Daly, M.J., et al., *High-resolution haplotype structure in the human genome.* Nat Genet, 2001. **29**(2): p. 229-32.
59. Goldstein, D.B., *Islands of linkage disequilibrium.* Nat Genet, 2001. **29**(2): p. 109-11.
60. Gabriel, S.B., et al., *The structure of haplotype blocks in the human genome.* Science, 2002. **296**(5576): p. 2225-9.
61. Shifman, S., et al., *Linkage disequilibrium patterns of the human genome across populations.* Hum Mol Genet, 2003. **12**(7): p. 771-6.
62. Bush, W.S. and J.H. Moore, *Chapter 11: Genome-wide association studies.* PLoS Comput Biol, 2012. **8**(12): p. e1002822.
63. International HapMap, C., *The International HapMap Project.* Nature, 2003. **426**(6968): p. 789-96.
64. Li, M., C. Li, and W. Guan, *Evaluation of coverage variation of SNP chips for genome-wide association studies.* Eur J Hum Genet, 2008. **16**(5): p. 635-43.
65. Wang, D.G., et al., *Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome.* Science, 1998. **280**(5366): p. 1077-82.
66. LaFramboise, T., *Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances.* Nucleic Acids Res, 2009. **37**(13): p. 4181-93.
67. Haines, J.L., et al., *Complement factor H variant increases the risk of age-related macular degeneration.* Science, 2005. **308**(5720): p. 419-21.
68. Wellcome Trust Case Control, C., *Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.* Nature, 2007. **447**(7145): p. 661-78.
69. Ioannidis, J.P., *Genetic associations: false or true?* Trends Mol Med, 2003. **9**(4): p. 135-8.
70. Ioannidis, J.P., N.A. Patsopoulos, and E. Evangelou, *Heterogeneity in meta-analyses of genome-wide association investigations.* PLoS One, 2007. **2**(9): p. e841.
71. Stephens, M., N.J. Smith, and P. Donnelly, *A new statistical method for haplotype reconstruction from population data.* Am J Hum Genet, 2001. **68**(4): p. 978-89.
72. Genomes Project, C., et al., *A map of human genome variation from population-scale sequencing.* Nature, 2010. **467**(7319): p. 1061-73.
73. Marchini, J. and B. Howie, *Genotype imputation for genome-wide association studies.* Nat Rev Genet, 2010. **11**(7): p. 499-511.

74. Willer, C.J., et al., *Six new loci associated with body mass index highlight a neuronal influence on body weight regulation*. Nat Genet, 2009. **41**(1): p. 25-34.
75. Zeggini, E., et al., *Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes*. Nat Genet, 2008. **40**(5): p. 638-45.
76. Prokopenko, I., et al., *Variants in MTNR1B influence fasting glucose levels*. Nat Genet, 2009. **41**(1): p. 77-81.
77. Willer, C.J., et al., *Newly identified loci that influence lipid concentrations and risk of coronary artery disease*. Nat Genet, 2008. **40**(2): p. 161-9.
78. Consortium, C.A.D., et al., *Large-scale association analysis identifies new risk loci for coronary artery disease*. Nat Genet, 2013. **45**(1): p. 25-33.
79. MacArthur, J., et al., *The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)*. Nucleic Acids Res, 2017. **45**(D1): p. D896-D901.
80. Yengo, L., et al., *Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry*. Hum Mol Genet, 2018.
81. Yang, J., et al., *Common SNPs explain a large proportion of the heritability for human height*. Nat Genet, 2010. **42**(7): p. 565-9.
82. Fuchsberger, C., et al., *The genetic architecture of type 2 diabetes*. Nature, 2016. **536**(7614): p. 41-47.
83. Dupuis, J., et al., *New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk*. Nat Genet, 2010. **42**(2): p. 105-16.
84. Liu, D.J., et al., *Exome-wide association study of plasma lipids in >300,000 individuals*. Nat Genet, 2017. **49**(12): p. 1758-1766.
85. Johansen, C.T., et al., *Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia*. Nat Genet, 2010. **42**(8): p. 684-7.
86. Chong, J.X., et al., *The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities*. Am J Hum Genet, 2015. **97**(2): p. 199-215.
87. LeMaire, S.A., et al., *Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1*. Nat Genet, 2011. **43**(10): p. 996-1000.
88. Newton-Cheh, C., et al., *Common variants at ten loci influence QT interval duration in the QTGEN Study*. Nat Genet, 2009. **41**(4): p. 399-406.
89. Hegele, R.A., *Plasma lipoproteins: genetic influences and clinical implications*. Nat Rev Genet, 2009. **10**(2): p. 109-21.
90. Antonarakis, S.E., et al., *Mendelian disorders and multifactorial traits: the big divide or one for all?* Nat Rev Genet, 2010. **11**(5): p. 380-4.
91. Consortium, U.K., et al., *The UK10K project identifies rare variants in health and disease*. Nature, 2015. **526**(7571): p. 82-90.
92. Locke, A.E., et al., *Genetic studies of body mass index yield new insights for obesity biology*. Nature, 2015. **518**(7538): p. 197-206.
93. Turcot, V., et al., *Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity*. Nat Genet, 2018. **50**(1): p. 26-41.
94. Shungin, D., et al., *New genetic loci link adipose and insulin biology to body fat distribution*. Nature, 2015. **518**(7538): p. 187-196.
95. Frayling, T.M., *Genome-wide association studies provide new insights into type 2 diabetes aetiology*. Nat Rev Genet, 2007. **8**(9): p. 657-62.
96. Morris, A.P., et al., *Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes*. Nat Genet, 2012. **44**(9): p. 981-90.
97. Lyssenko, V., et al., *Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion*. Nat Genet, 2009. **41**(1): p. 82-8.

98. Renstrom, F., et al., *Season-dependent associations of circadian rhythm-regulating loci (CRY1, CRY2 and MTNR1B) and glucose homeostasis: the GLACIER Study*. *Diabetologia*, 2015. **58**(5): p. 997-1005.
99. Pasquali, L., et al., *Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants*. *Nat Genet*, 2014. **46**(2): p. 136-143.
100. Lotta, L.A., et al., *Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance*. *Nat Genet*, 2017. **49**(1): p. 17-26.
101. Musunuru, K., et al., *From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus*. *Nature*, 2010. **466**(7307): p. 714-9.
102. Knowles, J.W. and E.A. Ashley, *Cardiovascular disease: The rise of the genetic risk score*. *PLoS Med*, 2018. **15**(3): p. e1002546.
103. Romanos, J., et al., *Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants*. *Gut*, 2014. **63**(3): p. 415-22.
104. Sharp, S.A., et al., *Clinical and research uses of genetic risk scores in type 1 diabetes*. *Curr Opin Genet Dev*, 2018. **50**: p. 96-102.
105. Loos, R.J.F. and A. Janssens, *Predicting Polygenic Obesity Using Genetic Information*. *Cell Metab*, 2017. **25**(3): p. 535-543.
106. Goodarzi, M.O., *Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications*. *Lancet Diabetes Endocrinol*, 2018. **6**(3): p. 223-236.
107. Afzal, S., et al., *Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts*. *BMJ*, 2014. **349**: p. g6330.
108. Cho, Y., et al., *Alcohol intake and cardiovascular risk factors: A Mendelian randomisation study*. *Sci Rep*, 2015. **5**: p. 18422.
109. Hagg, S., et al., *Adiposity as a cause of cardiovascular disease: a Mendelian randomization study*. *Int J Epidemiol*, 2015. **44**(2): p. 578-86.
110. Voight, B.F., et al., *Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study*. *Lancet*, 2012. **380**(9841): p. 572-80.
111. Haase, C.L., et al., *LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals*. *J Clin Endocrinol Metab*, 2012. **97**(2): p. E248-56.
112. Agerholm-Larsen, B., et al., *Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene*. *Circulation*, 2000. **101**(16): p. 1907-12.
113. Andersen, R.V., et al., *Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study*. *J Am Coll Cardiol*, 2003. **41**(11): p. 1972-82.
114. Frikke-Schmidt, R., et al., *Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease*. *JAMA*, 2008. **299**(21): p. 2524-32.
115. Bennett, D.A. and M.V. Holmes, *Mendelian randomisation in cardiovascular research: an introduction for clinicians*. *Heart*, 2017. **103**(18): p. 1400-1407.
116. Teslovich, T.M., et al., *Biological, clinical and population relevance of 95 loci for blood lipids*. *Nature*, 2010. **466**(7307): p. 707-13.
117. Pollin, T.I., et al., *A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection*. *Science*, 2008. **322**(5908): p. 1702-5.
118. Flannick, J., et al., *Loss-of-function mutations in SLC30A8 protect against type 2 diabetes*. *Nat Genet*, 2014. **46**(4): p. 357-63.
119. Pearson, E.R., et al., *Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study*. *Diabetes*, 2007. **56**(8): p. 2178-82.

120. Aslibekyan, S., et al., *Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate*. PLoS One, 2012. **7**(10): p. e48663.
121. Wheeler, E., et al., *Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis*. PLoS Med, 2017. **14**(9): p. e1002383.
122. Price, A.L., C.C. Spencer, and P. Donnelly, *Progress and promise in understanding the genetic basis of common diseases*. Proc Biol Sci, 2015. **282**(1821).
123. Pritchard, J.K., *Are rare variants responsible for susceptibility to complex diseases?* Am J Hum Genet, 2001. **69**(1): p. 124-37.
124. Boyle, E.A., Y.I. Li, and J.K. Pritchard, *An Expanded View of Complex Traits: From Polygenic to Omnigenic*. Cell, 2017. **169**(7): p. 1177-1186.
125. *The Haplotype Reference Consortium*. Available from: <http://www.haplotype-reference-consortium.org>.
126. Huang, J., et al., *Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel*. Nat Commun, 2015. **6**: p. 8111.
127. McCarthy, S., et al., *A reference panel of 64,976 haplotypes for genotype imputation*. Nat Genet, 2016. **48**(10): p. 1279-83.
128. Bustamante, C.D., et al., *Natural selection on protein-coding genes in the human genome*. Nature, 2005. **437**(7062): p. 1153-7.
129. Lim, E.T., et al., *Distribution and medical impact of loss-of-function variants in the Finnish founder population*. PLoS Genet, 2014. **10**(7): p. e1004494.
130. *UK Biobank Axiom Array*. Available from: <http://www.ukbiobank.ac.uk/scientists-3/uk-biobank-axiom-array/>.
131. Kotowski, I.K., et al., *A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol*. Am J Hum Genet, 2006. **78**(3): p. 410-22.
132. Cohen, J.C., et al., *Multiple rare alleles contribute to low plasma levels of HDL cholesterol*. Science, 2004. **305**(5685): p. 869-72.
133. Romeo, S., et al., *Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL*. Nat Genet, 2007. **39**(4): p. 513-6.
134. Sudlow, C., et al., *UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age*. PLoS Med, 2015. **12**(3): p. e1001779.
135. Sankar, P.L. and L.S. Parker, *The Precision Medicine Initiative's All of Us Research Program: an agenda for research on its ethical, legal, and social issues*. Genet Med, 2017. **19**(7): p. 743-750.
136. Chen, Z., et al., *China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up*. Int J Epidemiol, 2011. **40**(6): p. 1652-66.
137. Higgins, J.P., et al., *Measuring inconsistency in meta-analyses*. BMJ, 2003. **327**(7414): p. 557-60.
138. Nakaoka, H. and I. Inoue, *Meta-analysis of genetic association studies: methodologies, between-study heterogeneity and winner's curse*. J Hum Genet, 2009. **54**(11): p. 615-23.
139. Lin, D.Y. and P.F. Sullivan, *Meta-analysis of genome-wide association studies with overlapping subjects*. Am J Hum Genet, 2009. **85**(6): p. 862-72.
140. Galesloot, T.E., et al., *A comparison of multivariate genome-wide association methods*. PLoS One, 2014. **9**(4): p. e95923.
141. O'Reilly, P.F., et al., *MultiPhen: joint model of multiple phenotypes can increase discovery in GWAS*. PLoS One, 2012. **7**(5): p. e34861.
142. Furlotte, N.A. and E. Eskin, *Efficient multiple-trait association and estimation of genetic correlation using the matrix-variate linear mixed model*. Genetics, 2015. **200**(1): p. 59-68.
143. Denny, J.C., et al., *Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data*. Nat Biotechnol, 2013. **31**(12): p. 1102-10.

144. Denny, J.C., et al., *PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations*. *Bioinformatics*, 2010. **26**(9): p. 1205-10.
145. Ritchie, M.D., et al., *Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk*. *Circulation*, 2013. **127**(13): p. 1377-85.
146. Tyrrell, J., et al., *Gene-obesogenic environment interactions in the UK Biobank study*. *Int J Epidemiol*, 2017. **46**(2): p. 559-575.
147. Moore, R., et al., *A linear mixed model approach to study multivariate gene-environment interactions*. *bioRxiv*, 2018.
148. Emdin, C.A., et al., *Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease*. *Nat Commun*, 2018. **9**(1): p. 1613.
149. Dhandapany, P.S., et al., *A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia*. *Nat Genet*, 2009. **41**(2): p. 187-91.
150. Kurki, M.I., et al., *High risk population isolate reveals low frequency variants predisposing to intracranial aneurysms*. *PLoS Genet*, 2014. **10**(1): p. e1004134.
151. Consortium, S.T.D., et al., *Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population*. *JAMA*, 2014. **311**(22): p. 2305-14.
152. Genomes Project, C., et al., *An integrated map of genetic variation from 1,092 human genomes*. *Nature*, 2012. **491**(7422): p. 56-65.
153. Hatzikotoulas, K., A. Gilly, and E. Zeggini, *Using population isolates in genetic association studies*. *Brief Funct Genomics*, 2014. **13**(5): p. 371-7.
154. Asimit, J.L., et al., *Trans-ethnic study design approaches for fine-mapping*. *Eur J Hum Genet*, 2016. **24**(9): p. 1330-6.
155. Hu, Y., et al., *Discovery and fine-mapping of loci associated with MUFAs through trans-ethnic meta-analysis in Chinese and European populations*. *J Lipid Res*, 2017. **58**(5): p. 974-981.
156. Kuo, J.Z., et al., *Trans-ethnic fine mapping identifies a novel independent locus at the 3' end of CDKAL1 and novel variants of several susceptibility loci for type 2 diabetes in a Han Chinese population*. *Diabetologia*, 2013. **56**(12): p. 2619-28.
157. Magi, R., et al., *Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution*. *Hum Mol Genet*, 2017. **26**(18): p. 3639-3650.
158. Sebat, J., et al., *Strong association of de novo copy number mutations with autism*. *Science*, 2007. **316**(5823): p. 445-9.
159. Walsh, T., et al., *Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia*. *Science*, 2008. **320**(5875): p. 539-43.
160. Wheeler, E., et al., *Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity*. *Nat Genet*, 2013. **45**(5): p. 513-7.
161. Glessner, J.T., et al., *A genome-wide study reveals copy number variants exclusive to childhood obesity cases*. *Am J Hum Genet*, 2010. **87**(5): p. 661-6.
162. Gonzalez, J.R., et al., *A common 16p11.2 inversion underlies the joint susceptibility to asthma and obesity*. *Am J Hum Genet*, 2014. **94**(3): p. 361-72.
163. Mace, A., et al., *CNV-association meta-analysis in 191,161 European adults reveals new loci associated with anthropometric traits*. *Nat Commun*, 2017. **8**(1): p. 744.
164. Dajani, R., et al., *CNV Analysis Associates AKNAD1 with Type-2 Diabetes in Jordan Subpopulations*. *Sci Rep*, 2015. **5**: p. 13391.
165. Hayes, J.L., et al., *Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisation*. *Genomics*, 2013. **102**(3): p. 174-81.
166. Hehir-Kwa, J.Y., et al., *Genome-wide copy number profiling on high-density bacterial artificial chromosomes, single-nucleotide polymorphisms, and oligonucleotide microarrays: a platform comparison based on statistical power analysis*. *DNA Res*, 2007. **14**(1): p. 1-11.

167. Feng, Y., et al., *Improved molecular diagnosis by the detection of exonic deletions with target gene capture and deep sequencing*. *Genet Med*, 2015. **17**(2): p. 99-107.
168. Russo, C.D., et al., *Comparative study of aCGH and Next Generation Sequencing (NGS) for chromosomal microdeletion and microduplication screening*. *J Prenat Med*, 2014. **8**(3-4): p. 57-69.
169. Fromer, M., et al., *Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth*. *Am J Hum Genet*, 2012. **91**(4): p. 597-607.
170. Handsaker, R.E., et al., *Discovery and genotyping of genome structural polymorphism by sequencing on a population scale*. *Nat Genet*, 2011. **43**(3): p. 269-76.
171. Shin, S.Y., et al., *An atlas of genetic influences on human blood metabolites*. *Nat Genet*, 2014. **46**(6): p. 543-550.
172. Suhre, K., et al., *Human metabolic individuality in biomedical and pharmaceutical research*. *Nature*, 2011. **477**(7362): p. 54-60.
173. Kettunen, J., et al., *Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA*. *Nat Commun*, 2016. **7**: p. 11122.
174. Folkersen, L., et al., *Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease*. *PLoS Genet*, 2017. **13**(4): p. e1006706.
175. Global, B.M.I.M.C., et al., *Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents*. *Lancet*, 2016. **388**(10046): p. 776-86.
176. Ogden, C.L., M.D. Carroll, and K.M. Flegal, *Prevalence of obesity in the United States*. *JAMA*, 2014. **312**(2): p. 189-90.
177. Wardle, J., et al., *Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment*. *Am J Clin Nutr*, 2008. **87**(2): p. 398-404.
178. Silventoinen, K., et al., *Heritability of body size and muscle strength in young adulthood: a study of one million Swedish men*. *Genet Epidemiol*, 2008. **32**(4): p. 341-9.
179. Allison, D.B., et al., *The heritability of body mass index among an international sample of monozygotic twins reared apart*. *Int J Obes Relat Metab Disord*, 1996. **20**(6): p. 501-6.
180. Akiyama, M., et al., *Genome-wide association study identifies 112 new loci for body mass index in the Japanese population*. *Nat Genet*, 2017. **49**(10): p. 1458-1467.
181. Grarup, N., et al., *Loss-of-function variants in ADCY3 increase risk of obesity and type 2 diabetes*. *Nat Genet*, 2018. **50**(2): p. 172-174.
182. Justice, A.E., et al., *Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits*. *Nat Commun*, 2017. **8**: p. 14977.
183. Minster, R.L., et al., *A thrifty variant in CREBRF strongly influences body mass index in Samoans*. *Nat Genet*, 2016. **48**(9): p. 1049-1054.
184. Pigeyre, M., et al., *Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity*. *Clin Sci (Lond)*, 2016. **130**(12): p. 943-86.
185. Ramachandrapa, S., et al., *Rare variants in single-minded 1 (SIM1) are associated with severe obesity*. *J Clin Invest*, 2013. **123**(7): p. 3042-50.
186. Doche, M.E., et al., *Human SH2B1 mutations are associated with maladaptive behaviors and obesity*. *J Clin Invest*, 2012. **122**(12): p. 4732-6.
187. O'Rahilly, S. and I.S. Farooqi, *Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions*. *Diabetes*, 2008. **57**(11): p. 2905-10.
188. Saeed, S., et al., *Loss-of-function mutations in ADCY3 cause monogenic severe obesity*. *Nat Genet*, 2018. **50**(2): p. 175-179.
189. Clement, K., et al., *A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction*. *Nature*, 1998. **392**(6674): p. 398-401.
190. Krude, H., et al., *Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans*. *Nat Genet*, 1998. **19**(2): p. 155-7.

191. Montague, C.T., et al., *Congenital leptin deficiency is associated with severe early-onset obesity in humans*. *Nature*, 1997. **387**(6636): p. 903-8.
192. Gray, J., et al., *Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene*. *Diabetes*, 2006. **55**(12): p. 3366-71.
193. Collet, T.H., et al., *Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency*. *Mol Metab*, 2017. **6**(10): p. 1321-1329.
194. Yeo, G.S., et al., *A frameshift mutation in MC4R associated with dominantly inherited human obesity*. *Nat Genet*, 1998. **20**(2): p. 111-2.
195. Vaisse, C., et al., *A frameshift mutation in human MC4R is associated with a dominant form of obesity*. *Nat Genet*, 1998. **20**(2): p. 113-4.
196. Loos, R.J., et al., *Common variants near MC4R are associated with fat mass, weight and risk of obesity*. *Nat Genet*, 2008. **40**(6): p. 768-75.
197. Bulik, C.M. and D.B. Allison, *The genetic epidemiology of thinness*. *Obes Rev*, 2001. **2**(2): p. 107-15.
198. Costanzo, P.R. and S.S. Schiffman, *Thinness--not obesity--has a genetic component*. *Neurosci Biobehav Rev*, 1989. **13**(1): p. 55-8.
199. Magnusson, P.K. and F. Rasmussen, *Familial resemblance of body mass index and familial risk of high and low body mass index. A study of young men in Sweden*. *Int J Obes Relat Metab Disord*, 2002. **26**(9): p. 1225-31.
200. Laskarzewski, P.M., et al., *Familial obesity and leanness*. *Int J Obes*, 1983. **7**(6): p. 505-27.
201. Whitaker, K.L., et al., *The intergenerational transmission of thinness*. *Arch Pediatr Adolesc Med*, 2011. **165**(10): p. 900-5.
202. Jacquemont, S., et al., *Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus*. *Nature*, 2011. **478**(7367): p. 97-102.
203. Hasstedt, S.J., et al., *A Copy Number Variant on Chromosome 20q13.3 Implicated in Thinness and Severe Obesity*. *J Obes*, 2015. **2015**: p. 623431.
204. Hinney, A., et al., *Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants*. *PLoS One*, 2007. **2**(12): p. e1361.
205. Scannell Bryan, M., et al., *Genome-wide association studies and heritability estimates of body mass index related phenotypes in Bangladeshi adults*. *PLoS One*, 2014. **9**(8): p. e105062.
206. Braud, S., M. Ciufolini, and I. Harosh, *'Energy expenditure genes' or 'energy absorption genes': a new target for the treatment of obesity and Type II diabetes*. *Future Med Chem*, 2010. **2**(12): p. 1777-83.
207. Berndt, S.I., et al., *Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture*. *Nat Genet*, 2013. **45**(5): p. 501-12.
208. Speliotes, E.K., et al., *Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index*. *Nat Genet*, 2010. **42**(11): p. 937-48.
209. Cornish, K.M., et al., *Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample*. *Mol Psychiatry*, 2005. **10**(7): p. 686-98.
210. Emond, M.J., et al., *Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic *Pseudomonas aeruginosa* infection in cystic fibrosis*. *Nat Genet*, 2012. **44**(8): p. 886-9.
211. Lanktree, M.B., et al., *Extremes of unexplained variation as a phenotype: an efficient approach for genome-wide association studies of cardiovascular disease*. *Circ Cardiovasc Genet*, 2010. **3**(2): p. 215-21.

212. Zhou, Y.J., Y. Wang, and L.L. Chen, *Detecting the Common and Individual Effects of Rare Variants on Quantitative Traits by Using Extreme Phenotype Sampling*. *Genes* (Basel), 2016. **7**(1).
213. Morgan, J.F., F. Reid, and J.H. Lacey, *The SCOFF questionnaire: assessment of a new screening tool for eating disorders*. *BMJ*, 1999. **319**(7223): p. 1467-8.
214. Bochukova, E.G., et al., *Large, rare chromosomal deletions associated with severe early-onset obesity*. *Nature*, 2010. **463**(7281): p. 666-70.
215. University of Essex. Institute for Social and Economic Research and NatCen Social Research, *Understanding Society: Waves 1-5, 2009-2014 [computer file]*. 7th Edition. Colchester, Essex: UK Data Archive [distributor] November 2015 SN: 6614.
216. Wain, L.V., et al., *Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank*. *Lancet Respir Med*, 2015. **3**(10): p. 769-81.
217. Riveros-Mckay, F., et al., *Genetic architecture of human thinness compared to severe obesity*. *PLoS Genet*, 2018. **[in press]**.
218. Ma, C., et al., *Recommended joint and meta-analysis strategies for case-control association testing of single low-count variants*. *Genet Epidemiol*, 2013. **37**(6): p. 539-50.
219. Boyd, A., et al., *Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children*. *Int J Epidemiol*, 2013. **42**(1): p. 111-27.
220. Fraser, A., et al., *Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort*. *Int J Epidemiol*, 2013. **42**(1): p. 97-110.
221. Howie, B., J. Marchini, and M. Stephens, *Genotype imputation with thousands of genomes*. *G3* (Bethesda), 2011. **1**(6): p. 457-70.
222. Howie, B.N., P. Donnelly, and J. Marchini, *A flexible and accurate genotype imputation method for the next generation of genome-wide association studies*. *PLoS Genet*, 2009. **5**(6): p. e1000529.
223. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage analyses*. *Am J Hum Genet*, 2007. **81**(3): p. 559-75.
224. Price, A.L., et al., *Principal components analysis corrects for stratification in genome-wide association studies*. *Nat Genet*, 2006. **38**(8): p. 904-9.
225. Manichaikul, A., et al., *Robust relationship inference in genome-wide association studies*. *Bioinformatics*, 2010. **26**(22): p. 2867-73.
226. Marchini, J., et al., *A new multipoint method for genome-wide association studies by imputation of genotypes*. *Nat Genet*, 2007. **39**(7): p. 906-13.
227. Loh, P.R., et al., *Efficient Bayesian mixed-model analysis increases association power in large cohorts*. *Nat Genet*, 2015. **47**(3): p. 284-90.
228. Bulik-Sullivan, B., et al., *An atlas of genetic correlations across human diseases and traits*. *Nat Genet*, 2015. **47**(11): p. 1236-41.
229. *Measuring and interpreting BMI in Children :: Public Health England Obesity Knowledge and Intelligence team*. 19th December 2016]; Available from: https://www.noo.org.uk/NOO_about_obesity/measurement/children.
230. Denaxas, S.C., et al., *Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER)*. *Int J Epidemiol*, 2012. **41**(6): p. 1625-38.
231. Zheng, J., et al., *LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis*. *Bioinformatics*, 2017. **33**(2): p. 272-279.
232. Harrell, F.E., *rms: R functions for biostatistical/epidemiologic modeling, testing, estimation, validation, graphics, prediction, and typesetting by storing enhanced model design attributes in the fit*, 2013. *Implements methods in Regression Modeling Strategies*, New York:Springer, 2001.

233. R Development Core Team, *R: A Language and Environment for Statistical Computing*. 2011, R Foundation for Statistical Computing: Vienna, Austria.
234. Gauderman, W. and J. Morrison, *QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies*, <http://hydra.usc.edu/gxe>. 2006.
235. Canela-Xandri, O., et al., *A new tool called DISSECT for analysing large genomic data sets using a Big Data approach*. *Nat Commun*, 2015. **6**: p. 10162.
236. Bradfield, J.P., et al., *A genome-wide association meta-analysis identifies new childhood obesity loci*. *Nat Genet*, 2012. **44**(5): p. 526-31.
237. Southam, L., et al., *Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits*. *Nat Commun*, 2017. **8**: p. 15606.
238. Willer, C.J., Y. Li, and G.R. Abecasis, *METAL: fast and efficient meta-analysis of genomewide association scans*. *Bioinformatics*, 2010. **26**(17): p. 2190-1.
239. Xu, C., et al., *Estimating genome-wide significance for whole-genome sequencing studies*. *Genet Epidemiol*, 2014. **38**(4): p. 281-90.
240. Hinney, A., A.L. Volckmar, and N. Knoll, *Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis*. *Prog Mol Biol Transl Sci*, 2013. **114**: p. 147-91.
241. Geller, F., et al., *Melanocortin-4 receptor gene variant I103 is negatively associated with obesity*. *Am J Hum Genet*, 2004. **74**(3): p. 572-81.
242. Klimentidis, Y.C., et al., *Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE*. *Int J Obes (Lond)*, 2018.
243. Mitchell, J.A., et al., *Obesity-susceptibility loci and the tails of the pediatric BMI distribution*. *Obesity (Silver Spring)*, 2013. **21**(6): p. 1256-60.
244. Beyerlein, A., et al., *Genetic markers of obesity risk: stronger associations with body composition in overweight compared to normal-weight children*. *PLoS One*, 2011. **6**(4): p. e19057.
245. Chan, Y., et al., *Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals*. *PLoS Genet*, 2011. **7**(12): p. e1002439.
246. Young, A.I., F. Wauthier, and P. Donnelly, *Multiple novel gene-by-environment interactions modify the effect of FTO variants on body mass index*. *Nat Commun*, 2016. **7**: p. 12724.
247. Winkler, T.W., et al., *The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study*. *PLoS Genet*, 2015. **11**(10): p. e1005378.
248. Qi, Q., et al., *FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals*. *Hum Mol Genet*, 2014. **23**(25): p. 6961-72.
249. Bjornland, T., et al., *Assessing gene-environment interaction effects of FTO, MC4R and lifestyle factors on obesity using an extreme phenotype sampling design: Results from the HUNT study*. *PLoS One*, 2017. **12**(4): p. e0175071.
250. Shungin, D., et al., *New genetic loci link adipose and insulin biology to body fat distribution*. *Nature*, 2015. **518**(7538): p. 187-96.
251. Tachmazidou, I., et al., *Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits*. *Am J Hum Genet*, 2017. **100**(6): p. 865-884.
252. Lango Allen, H., et al., *Hundreds of variants clustered in genomic loci and biological pathways affect human height*. *Nature*, 2010. **467**(7317): p. 832-8.
253. Wen, W., et al., *Genome-wide association studies in East Asians identify new loci for waist-hip ratio and waist circumference*. *Sci Rep*, 2016. **6**: p. 17958.
254. Shaheen, R., et al., *A founder CEP120 mutation in Jeune asphyxiating thoracic dystrophy expands the role of centriolar proteins in skeletal ciliopathies*. *Hum Mol Genet*, 2015. **24**(5): p. 1410-9.

255. Roosing, S., et al., *Mutations in CEP120 cause Joubert syndrome as well as complex ciliopathy phenotypes*. J Med Genet, 2016. **53**(9): p. 608-15.
256. Athersuch, T.J. and H.C. Keun, *Metabolic profiling in human exposome studies*. Mutagenesis, 2015. **30**(6): p. 755-62.
257. Lydic, T.A. and Y.H. Goo, *Lipidomics unveils the complexity of the lipidome in metabolic diseases*. Clin Transl Med, 2018. **7**(1): p. 4.
258. Arsenault, B.J., S.M. Boekholdt, and J.J. Kastelein, *Lipid parameters for measuring risk of cardiovascular disease*. Nat Rev Cardiol, 2011. **8**(4): p. 197-206.
259. Nordestgaard, B.G. and A. Varbo, *Triglycerides and cardiovascular disease*. Lancet, 2014. **384**(9943): p. 626-635.
260. Varbo, A., M. Benn, and B.G. Nordestgaard, *Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment*. Pharmacol Ther, 2014. **141**(3): p. 358-67.
261. Wyler von Ballmoos, M.C., B. Haring, and F.M. Sacks, *The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis*. J Clin Lipidol, 2015. **9**(4): p. 498-510.
262. Geng, P., et al., *Serum mannose-binding lectin is a strong biomarker of diabetic retinopathy in chinese patients with diabetes*. Diabetes Care, 2015. **38**(5): p. 868-75.
263. Trpkovic, A., et al., *Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases*. Crit Rev Clin Lab Sci, 2015. **52**(2): p. 70-85.
264. *Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society*. Eur Heart J, 1987. **8**(1): p. 77-88.
265. Gordon, T., et al., *High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study*. Am J Med, 1977. **62**(5): p. 707-14.
266. Hokanson, J.E. and M.A. Austin, *Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies*. J Cardiovasc Risk, 1996. **3**(2): p. 213-9.
267. UK, N., 'Chronic kidney disease - Diagnosis - NHS Choices', [online] Available from: <https://www.nhs.uk/conditions/kidney-disease/diagnosis/> (Accessed 02 July 2018). . 2018.
268. Chaussain, J.L., et al., *Serum branched-chain amino acids in the diagnosis of hyperinsulinism in infancy*. J Pediatr, 1980. **97**(6): p. 923-6.
269. Adeva, M.M., et al., *Insulin resistance and the metabolism of branched-chain amino acids in humans*. Amino Acids, 2012. **43**(1): p. 171-81.
270. Wang, Q., et al., *Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation*. Diabetes Care, 2017. **40**(12): p. 1779-1786.
271. Hobbs, H.H., M.S. Brown, and J.L. Goldstein, *Molecular genetics of the LDL receptor gene in familial hypercholesterolemia*. Hum Mutat, 1992. **1**(6): p. 445-66.
272. Shichiri, M., A. Tanaka, and Y. Hirata, *Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene complex*. Gene Ther, 2003. **10**(9): p. 827-31.
273. Soria, L.F., et al., *Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100*. Proc Natl Acad Sci U S A, 1989. **86**(2): p. 587-91.
274. Gebhard, C., et al., *Apolipoprotein B antisense inhibition--update on mipomersen*. Curr Pharm Des, 2013. **19**(17): p. 3132-42.
275. Abifadel, M., et al., *Mutations in PCSK9 cause autosomal dominant hypercholesterolemia*. Nat Genet, 2003. **34**(2): p. 154-6.
276. Duff, C.J. and N.M. Hooper, *PCSK9: an emerging target for treatment of hypercholesterolemia*. Expert Opin Ther Targets, 2011. **15**(2): p. 157-68.
277. Duell, P.B., et al., *Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia*. J Clin Lipidol, 2016. **10**(4): p. 1011-1021.

278. Karatasakis, A., et al., *Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials*. J Am Heart Assoc, 2017. **6**(12).
279. Asselbergs, F.W., et al., *Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci*. Am J Hum Genet, 2012. **91**(5): p. 823-38.
280. Willer, C.J., et al., *Discovery and refinement of loci associated with lipid levels*. Nat Genet, 2013. **45**(11): p. 1274-1283.
281. Albrechtsen, A., et al., *Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes*. Diabetologia, 2013. **56**(2): p. 298-310.
282. Peloso, G.M., et al., *Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks*. Am J Hum Genet, 2014. **94**(2): p. 223-32.
283. Surakka, I., et al., *The impact of low-frequency and rare variants on lipid levels*. Nat Genet, 2015. **47**(6): p. 589-97.
284. Tang, C.S., et al., *Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese*. Nat Commun, 2015. **6**: p. 10206.
285. Natarajan, P., et al., *Deep-coverage whole genome sequences and blood lipids among 16,324 individuals*. bioRxiv, 2017.
286. White, J., et al., *Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis*. Lancet Diabetes Endocrinol, 2016. **4**(4): p. 327-36.
287. Keenan, T., et al., *Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study*. J Am Coll Cardiol, 2016. **67**(4): p. 407-416.
288. Davis, J.P., et al., *Common, low-frequency, and rare genetic variants associated with lipoprotein subclasses and triglyceride measures in Finnish men from the METSIM study*. PLoS Genet, 2017. **13**(10): p. e1007079.
289. Teslovich, T.M., et al., *Identification of seven novel loci associated with amino acid levels using single-variant and gene-based tests in 8545 Finnish men from the METSIM study*. Hum Mol Genet, 2018. **27**(9): p. 1664-1674.
290. Dewey, F.E., et al., *Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease*. N Engl J Med, 2016. **374**(12): p. 1123-33.
291. Dewey, F.E., et al., *Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study*. Science, 2016. **354**(6319).
292. Moore, C., et al., *The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trial*. Trials, 2014. **15**: p. 363.
293. Astle, W.J., et al., *The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease*. Cell, 2016. **167**(5): p. 1415-1429 e19.
294. Singh, T., et al., *Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders*. Nat Neurosci, 2016. **19**(4): p. 571-7.
295. Li, H. and R. Durbin, *Fast and accurate short read alignment with Burrows-Wheeler transform*. Bioinformatics, 2009. **25**(14): p. 1754-60.
296. McKenna, A., et al., *The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data*. Genome Res, 2010. **20**(9): p. 1297-303.
297. Jun, G., et al., *Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data*. Am J Hum Genet, 2012. **91**(5): p. 839-48.
298. Soininen, P., et al., *High-throughput serum NMR metabolomics for cost-effective holistic studies on systemic metabolism*. Analyst, 2009. **134**(9): p. 1781-5.
299. Pinero, J., et al., *DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants*. Nucleic Acids Res, 2017. **45**(D1): p. D833-D839.
300. Pinero, J., et al., *DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes*. Database (Oxford), 2015. **2015**: p. bav028.

301. Kanehisa, M., et al., *KEGG: new perspectives on genomes, pathways, diseases and drugs*. Nucleic Acids Res, 2017. **45**(D1): p. D353-D361.
302. Kanehisa, M. and S. Goto, *KEGG: kyoto encyclopedia of genes and genomes*. Nucleic Acids Res, 2000. **28**(1): p. 27-30.
303. Kanehisa, M., et al., *KEGG as a reference resource for gene and protein annotation*. Nucleic Acids Res, 2016. **44**(D1): p. D457-62.
304. Fabregat, A., et al., *The Reactome Pathway Knowledgebase*. Nucleic Acids Res, 2018. **46**(D1): p. D649-D655.
305. Milacic, M., et al., *Annotating cancer variants and anti-cancer therapeutics in reactome*. Cancers (Basel), 2012. **4**(4): p. 1180-211.
306. Zaykin, D.V., *Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis*. J Evol Biol, 2011. **24**(8): p. 1836-41.
307. Dewey, M., *metap: meta-analysis of significance values*. 2018.
308. Rhee, E.P., et al., *An exome array study of the plasma metabolome*. Nat Commun, 2016. **7**: p. 12360.
309. Aschard, H., et al., *Adjusting for heritable covariates can bias effect estimates in genome-wide association studies*. Am J Hum Genet, 2015. **96**(2): p. 329-39.
310. Aschard, H., et al., *Covariate selection for association screening in multiphenotype genetic studies*. Nat Genet, 2017. **49**(12): p. 1789-1795.
311. Drenos, F., et al., *Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects*. Circ Cardiovasc Genet, 2016. **9**(3): p. 231-9.
312. Grevengoed, T.J., et al., *Acyl-CoA synthetase 1 deficiency alters cardiolipin species and impairs mitochondrial function*. J Lipid Res, 2015. **56**(8): p. 1572-82.
313. Yan, S., et al., *Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update*. World J Gastroenterol, 2015. **21**(12): p. 3492-8.
314. Zirath, H., et al., *MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells*. Proc Natl Acad Sci U S A, 2013. **110**(25): p. 10258-63.
315. Gopinathrao, G., *Image for "Regulation of pyruvate dehydrogenase (PDH) complex". Reactome, release 65, doi:10.3180/REACT_12528.1*. 2007.
316. Li, L.O., et al., *Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition*. J Biol Chem, 2009. **284**(41): p. 27816-26.
317. Scott, R.A., et al., *An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans*. Diabetes, 2017. **66**(11): p. 2888-2902.
318. Yang, L., et al., *High expression of long chain acyl-coenzyme A synthetase 1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarction*. Exp Ther Med, 2017. **14**(5): p. 4065-4072.
319. Brodeur, G.M., et al., *Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage*. Science, 1984. **224**(4653): p. 1121-4.
320. Emanuel, B.S., et al., *N-myc amplification in multiple homogeneously staining regions in two human neuroblastomas*. Proc Natl Acad Sci U S A, 1985. **82**(11): p. 3736-40.
321. Sato, T., et al., *Molecular cloning and characterization of a novel human beta 1,4-N-acetylgalactosaminyltransferase, beta 4GalNAc-T3, responsible for the synthesis of N,N'-diacetyllactosediamine, galNAc beta 1-4GlcNAc*. J Biol Chem, 2003. **278**(48): p. 47534-44.
322. Morgan, H., et al., *EuroPhenome: a repository for high-throughput mouse phenotyping data*. Nucleic Acids Res, 2010. **38**(Database issue): p. D577-85.
323. Wood, A.R., et al., *Defining the role of common variation in the genomic and biological architecture of adult human height*. Nat Genet, 2014. **46**(11): p. 1173-86.
324. Jin, J., et al., *Systematic analysis and nomenclature of mammalian F-box proteins*. Genes Dev, 2004. **18**(21): p. 2573-80.

325. Zhang, S., et al., *The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility*. Nutr Metab (Lond), 2014. **11**(1): p. 10.
326. Holmes, M.V., et al., *Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke*. J Am Coll Cardiol, 2018. **71**(6): p. 620-632.
327. Dron, J.S., et al., *Polygenic determinants in extremes of high-density lipoprotein cholesterol*. J Lipid Res, 2017. **58**(11): p. 2162-2170.
328. Lange, L.A., et al., *Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol*. Am J Hum Genet, 2014. **94**(2): p. 233-45.
329. Diabetes.co.uk. *Normal and Diabetic Blood Sugar Level Ranges*. 2018 [Accessed: 11-08-2018]; Available from: https://www.diabetes.co.uk/diabetes_care/blood-sugar-level-ranges.html.
330. Drzewoski, J. and L. Czupryniak, *Concordance between fasting and 2-h post-glucose challenge criteria for the diagnosis of diabetes mellitus and glucose intolerance in high risk individuals*. Diabet Med, 2001. **18**(1): p. 29-31.
331. Faerch, K., et al., *Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study*. Lancet Diabetes Endocrinol, 2013. **1**(1): p. 43-51.
332. Decode Study Group, t.E.D.E.G., *Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria*. Arch Intern Med, 2001. **161**(3): p. 397-405.
333. American Diabetes, A., *Diagnosis and classification of diabetes mellitus*. Diabetes Care, 2014. **37 Suppl 1**: p. S81-90.
334. Paschou, S.A., et al., *Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management*. J Clin Endocrinol Metab, 2017. **102**(10): p. 3621-3634.
335. Phung, O.J., et al., *Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis*. Diabetes Obes Metab, 2014. **16**(5): p. 410-7.
336. Saulsberry, W.J., et al., *Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes*. Int J Clin Pract, 2015. **69**(11): p. 1221-35.
337. Koenig, R.J., et al., *Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus*. N Engl J Med, 1976. **295**(8): p. 417-20.
338. Sidorenkov, G., et al., *A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness*. PLoS One, 2011. **6**(9): p. e24278.
339. Ghazanfari, Z., et al., *A Comparison of HbA1c and Fasting Blood Sugar Tests in General Population*. Int J Prev Med, 2010. **1**(3): p. 187-94.
340. Roberts, W.L., et al., *Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods*. Clin Chem, 2005. **51**(4): p. 776-8.
341. Son, J.I., et al., *Hemoglobin a1c may be an inadequate diagnostic tool for diabetes mellitus in anemic subjects*. Diabetes Metab J, 2013. **37**(5): p. 343-8.
342. Herman, W.H., et al., *Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program*. Diabetes Care, 2007. **30**(10): p. 2453-7.
343. Cohen, R.M., S. Haggerty, and W.H. Herman, *HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction?* J Clin Endocrinol Metab, 2010. **95**(12): p. 5203-6.
344. Simonis-Bik, A.M., et al., *The heritability of HbA1c and fasting blood glucose in different measurement settings*. Twin Res Hum Genet, 2008. **11**(6): p. 597-602.
345. Snieder, H., et al., *HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins*. Diabetes, 2001. **50**(12): p. 2858-63.
346. Chen, P., et al., *Multiple nonglycemic genomic loci are newly associated with blood level of glycated hemoglobin in East Asians*. Diabetes, 2014. **63**(7): p. 2551-62.

347. Franklin, C.S., et al., *The TCF7L2 diabetes risk variant is associated with HbA(1)(C) levels: a genome-wide association meta-analysis*. *Ann Hum Genet*, 2010. **74**(6): p. 471-8.
348. Pare, G., et al., *Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study*. *PLoS Genet*, 2008. **4**(12): p. e1000312.
349. Ryu, J. and C. Lee, *Association of glycosylated hemoglobin with the gene encoding CDKAL1 in the Korean Association Resource (KARE) study*. *Hum Mutat*, 2012. **33**(4): p. 655-9.
350. Soranzo, N., et al., *Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways*. *Diabetes*, 2010. **59**(12): p. 3229-39.
351. Danese, E., et al., *Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes*. *J Diabetes Sci Technol*, 2015. **9**(2): p. 169-76.
352. Armbruster, D.A., *Fructosamine: structure, analysis, and clinical usefulness*. *Clin Chem*, 1987. **33**(12): p. 2153-63.
353. Sacks, D.B., *A1C versus glucose testing: a comparison*. *Diabetes Care*, 2011. **34**(2): p. 518-23.
354. Little, R.R., et al., *Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care*. *Clin Chem*, 2011. **57**(2): p. 205-14.
355. Juraschek, S.P., et al., *Alternative markers of hyperglycemia and risk of diabetes*. *Diabetes Care*, 2012. **35**(11): p. 2265-70.
356. Selvin, E., et al., *Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study*. *Lancet Diabetes Endocrinol*, 2014. **2**(4): p. 279-88.
357. Hom, F.G., B. Ettinger, and M.J. Lin, *Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population*. *Acta Diabetol*, 1998. **35**(1): p. 48-51.
358. Smart, L.M., et al., *Comparison of fructosamine with glycosylated hemoglobin and plasma proteins as measures of glycemic control*. *Diabetes Care*, 1988. **11**(5): p. 433-6.
359. Zafon, C., et al., *Variables involved in the discordance between HbA1c and fructosamine: the glycation gap revisited*. *PLoS One*, 2013. **8**(6): p. e66696.
360. Cohen, R.M., et al., *Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy*. *Diabetes Care*, 2003. **26**(1): p. 163-7.
361. Rodriguez-Segade, S., et al., *Influence of the glycation gap on the diagnosis of type 2 diabetes*. *Acta Diabetol*, 2015. **52**(3): p. 453-9.
362. Cohen, R.M., et al., *Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins*. *Diabetes Care*, 2006. **29**(8): p. 1739-43.
363. Loomis, S.J., et al., *Genome-Wide Association Study of Serum Fructosamine and Glycated Albumin in Adults Without Diagnosed Diabetes: Results From the Atherosclerosis Risk in Communities Study*. *Diabetes*, 2018. **67**(8): p. 1684-1696.
364. O'Connell, J., et al., *Haplotype estimation for biobank-scale data sets*. *Nat Genet*, 2016. **48**(7): p. 817-20.
365. Machiela, M.J. and S.J. Chanock, *LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants*. *Bioinformatics*, 2015. **31**(21): p. 3555-7.
366. Manning, A.K., et al., *A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance*. *Nat Genet*, 2012. **44**(6): p. 659-69.
367. Scott, R.A., et al., *Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways*. *Nat Genet*, 2012. **44**(9): p. 991-1005.

368. Mahajan, A., et al., *Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus*. PLoS Genet, 2015. **11**(1): p. e1004876.
369. Strawbridge, R.J., et al., *Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes*. Diabetes, 2011. **60**(10): p. 2624-34.
370. Saxena, R., et al., *Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge*. Nat Genet, 2010. **42**(2): p. 142-8.
371. Kim, Y.J., et al., *Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits*. Nat Genet, 2011. **43**(10): p. 990-5.
372. Hwang, J.Y., et al., *Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians*. Diabetes, 2015. **64**(1): p. 291-8.
373. Liu, C.T., et al., *Trans-ethnic Meta-analysis and Functional Annotation Illuminates the Genetic Architecture of Fasting Glucose and Insulin*. Am J Hum Genet, 2016. **99**(1): p. 56-75.
374. Huyghe, J.R., et al., *Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion*. Nat Genet, 2013. **45**(2): p. 197-201.
375. Wessel, J., et al., *Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility*. Nat Commun, 2015. **6**: p. 5897.
376. Go, M.J., et al., *New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population*. J Hum Genet, 2013. **58**(6): p. 362-5.
377. Horikoshi, M., et al., *Discovery and Fine-Mapping of Glycaemic and Obesity-Related Trait Loci Using High-Density Imputation*. PLoS Genet, 2015. **11**(7): p. e1005230.
378. Chen, G., et al., *Genome-wide association study identifies novel loci association with fasting insulin and insulin resistance in African Americans*. Hum Mol Genet, 2012. **21**(20): p. 4530-6.
379. Henny, J., et al., *Detetermination of reference values for a colorimetric fructosamine assay*. Vol. 38. 1992. 153-160.
380. Sherwani, S.I., et al., *Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients*. Biomark Insights, 2016. **11**: p. 95-104.
381. Franceschini, N., et al., *Discovery and fine mapping of serum protein loci through transethnic meta-analysis*. Am J Hum Genet, 2012. **91**(4): p. 744-53.
382. Kanai, M., et al., *Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases*. Nat Genet, 2018. **50**(3): p. 390-400.
383. Martin, C.C., et al., *Cloning and characterization of the human and rat islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes*. J Biol Chem, 2001. **276**(27): p. 25197-207.
384. Wang, Y., et al., *Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype*. Diabetologia, 2007. **50**(4): p. 774-8.
385. Pound, L.D., et al., *G6PC2: a negative regulator of basal glucose-stimulated insulin secretion*. Diabetes, 2013. **62**(5): p. 1547-56.
386. Honore, B. and H. Vorum, *The CREC family, a novel family of multiple EF-hand, low-affinity Ca(2+)-binding proteins localised to the secretory pathway of mammalian cells*. FEBS Lett, 2000. **466**(1): p. 11-8.
387. Consortium, G.T., *The Genotype-Tissue Expression (GTEx) project*. Nat Genet, 2013. **45**(6): p. 580-5.
388. Chaudhury, C., et al., *The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan*. J Exp Med, 2003. **197**(3): p. 315-22.
389. Pyzik, M., et al., *Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury*. Proc Natl Acad Sci U S A, 2017. **114**(14): p. E2862-E2871.

390. Turley, P., et al., *Multi-trait analysis of genome-wide association summary statistics using MTAG*. *Nat Genet*, 2018. **50**(2): p. 229-237.
391. Dimas, A.S., et al., *Impact of type 2 diabetes susceptibility variants on quantitative glycaemic traits reveals mechanistic heterogeneity*. *Diabetes*, 2014. **63**(6): p. 2158-71.
392. Gurdasani, D., et al., *The African Genome Variation Project shapes medical genetics in Africa*. *Nature*, 2015. **517**(7534): p. 327-32.
393. UK Biobank, *Nightingale Health and UK Biobank announces major initiative to analyse half a million blood samples to facilitate global medical research*. 2018, [Press Release] Retrieved from: <http://www.ukbiobank.ac.uk/2018/06/nightingale-health-and-uk-biobank-announces-major-initiative-to-analyse-half-a-million-blood-samples-to-facilitate-global-medical-research/>.
394. UK Biobank, *Whole genome sequencing will 'transform the research landscape for a wide range of diseases'*. 2018, [Prese Release] Retrieved from: <http://www.ukbiobank.ac.uk/2018/04/whole-genome-sequencing-will-transform-the-research-landscape-for-a-wide-range-of-diseases/>.
395. Cross-Disorder Group of the Psychiatric Genomics, C., et al., *Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs*. *Nat Genet*, 2013. **45**(9): p. 984-94.
396. Andreassen, O.A., et al., *Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci*. *Mol Psychiatry*, 2015. **20**(2): p. 207-14.
397. Moutsianas, L., et al., *The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease*. *PLoS Genet*, 2015. **11**(4): p. e1005165.
398. Fowler, D.M. and S. Fields, *Deep mutational scanning: a new style of protein science*. *Nat Methods*, 2014. **11**(8): p. 801-7.
399. Chen, S., et al., *An interactome perturbation framework prioritizes damaging missense mutations for developmental disorders*. *Nat Genet*, 2018. **50**(7): p. 1032-1040.
400. Hendricks, A.E., et al., *Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity*. *Sci Rep*, 2017. **7**(1): p. 4394.
401. Singh, T., et al., *The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability*. *Nat Genet*, 2017. **49**(8): p. 1167-1173.
402. Short, P.J., et al., *De novo mutations in regulatory elements in neurodevelopmental disorders*. *Nature*, 2018. **555**(7698): p. 611-616.
403. Siggens, L. and K. Ekwall, *Epigenetics, chromatin and genome organization: recent advances from the ENCODE project*. *J Intern Med*, 2014. **276**(3): p. 201-14.
404. Roadmap Epigenomics, C., et al., *Integrative analysis of 111 reference human epigenomes*. *Nature*, 2015. **518**(7539): p. 317-30.
405. Martens, J.H. and H.G. Stunnenberg, *BLUEPRINT: mapping human blood cell epigenomes*. *Haematologica*, 2013. **98**(10): p. 1487-9.
406. Li, X., et al., *The impact of rare variation on gene expression across tissues*. *Nature*, 2017. **550**(7675): p. 239-243.
407. Inoue, F. and N. Ahituv, *Decoding enhancers using massively parallel reporter assays*. *Genomics*, 2015. **106**(3): p. 159-164.